Clinical Trial Detail

NCT ID NCT02514551
Title A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Eli Lilly and Company
Indications

gastroesophageal junction adenocarcinoma

gastric adenocarcinoma

Therapies

Paclitaxel

Ramucirumab

Age Groups: adult

No variant requirements are available.